Yttrium 90 radioembolization: The horizon is changing for patients with intermediate and advanced hepatocellular carcinoma†‡
See Article on Page 1826
Potential conflict of interest: Dr. Piscaglia consults for and is on the speakers' bureau of Bayer. He is also on the speakers' bureau of Siemens and Roche. He received grants from Bracco. Dr. Bolondi is on the speakers' bureau of Sirtex.
No abstract is available for this article.